AZD5863 for Advanced Solid Cancers

Phase 1 & 2

Recruiting

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from the start of study treatment/date of randomization to death (to be followed-up for approx. 2 years)

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if a new drug can safely and effectively treat advanced solid tumors. #CancerResearch

Who is the study for?

Adults over 18 with advanced solid tumors like pancreatic, esophageal, or stomach cancer can join this trial if they've had at least one prior treatment for advanced cancer. They need a life expectancy of 12 weeks or more, measurable tumor lesions, and positive CLDN18.2 expression in their tumor cells. Good physical health is required (ECOG PS: 0-1), as well as proper organ and bone marrow function.

What is being tested?

The study tests AZD5863, an experimental drug that targets specific proteins on T cells and cancer cells to fight the tumor. It's given to see if it's safe and effective against certain types of solid tumors that have spread or cannot be removed by surgery.

What are the potential side effects?

Potential side effects may include reactions related to the immune system such as cytokine release syndrome (CRS) which can cause fever and fatigue; neurotoxicity; inflammation-related symptoms affecting different organs; infection risks due to immune response changes; plus common drug-related adverse events.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from the start of study treatment/date of randomization to death (to be followed-up for approx. 2 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from the start of study treatment/date of randomization to death (to be followed-up for approx. 2 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from the start of study treatment/date of randomization to death (to be followed-up for approx. 2 years) for reporting.